

# Strategy Certificates

Linked to the Global Energy ex-MENA Basket (USD) Issued by UBS AG

Cash settled  
 SVSP Product Type: Tracker Certificates (1300) Valor: 12972196 ; ISIN:  
 CH0129721962

**Amendment as of 1 January 2017: added paragraph regarding US Withholding Tax (regulation 871m)**

**Expiration has been extended to 04 May 2021**

## Final Terms

**This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.**

### 1. Description of the Product

|  |  |
|--|--|
| <b>Information on Underlying</b>   | The Global Energy ex-MENA Basket (USD) will allow investors to participate in large capitalisation Global Energy equities, which will benefit from high oil and gas prices without any exposure to Middle East and North African instability, as the companies have very low asset risk in the region.   |
| Underlying(s)  | Description  |
| <b>Global Energy ex-MENA (USD) Reference-Portfolio (the "Reference-Portfolio")</b> | The <b>Global Energy ex-MENA (USD) Reference-Portfolio</b> (the " <b>Reference-Portfolio</b> ") is a notional US Dollar ("USD") denominated Reference-Portfolio, actively managed, created and maintained by Nevastar Finance Ltd. (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of stocks listed globally (the " <b>Constituents</b> ") and (ii) from time to time, a cash position (the " <b>Cash Position</b> "), which together with the Constituents shall be referred to as the " <b>Reference-Portfolio Components</b> "), less fees and expenses. Net dividends, if any, of each Constituent in the basket will be re-invested. The Reference-Portfolio Advisor manages the Reference-Portfolio in accordance with the attached Reference-Portfolio Guidelines (Annex). |

#### Product Details

|                                   |   |
|-----------------------------------|---|
| Security Numbers                  | Valor: 12972196 / ISIN: CH0129721962 / WKN: UB7AAU  |
| Issue Size                        | Up to 20'000 Units (with reopening clause)  |
| Initial Reference-Portfolio Level | USD 1'000.00  |
| Issue Price                       | USD 1'000.00 (100.00% of Initial Reference-Portfolio Level)   |
| Settlement Currency               | USD   |
| Currency Treatment                | The Reference-Portfolio can invest and be exposed to Reference-Portfolio Components in currencies other than the Settlement Currency. <b>The currency risk is not hedged.</b> |

#### Dates

|                           |             |
|---------------------------|-------------|
| Launch Date               | 05 May 2011 |
| Pricing Date              | 05 May 2011 |
| Payment Date (Issue Date) | 12 May 2011 |
| Last Trading Day          | 04 May 2021 |

Institutional Investors: 41-44-239 16 10\*  
Private Investors: [derivatives@ubs.com](mailto:derivatives@ubs.com)

Internet: [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest)

|  |  |
|--|--|
| Expiration Date ("Expiry")               | 04 May 2021 (subject to Market Disruption Event provisions), extendable at the option of the Issuer for additional 5-year periods, on a rolling basis, with a notice period of 1 year. |
| Redemption Date                          | 5 Business Days following the Expiration Date (currently expected to be 11 May 2021), or the Early Expiration Date (as applicable) (subject to Market Disruption Event provisions).    |
| Closing Date<br>(for Swiss tax purposes) | 1 January, for the first time 1 January 2012   |

#### Redemption

---

**Redemption Amount** The Investor is entitled to receive from the Issuer on the Redemption Date or the Early Redemption Date, as applicable, an amount in the Settlement Currency based on the closing of the Reference-Portfolio Levels on the Expiration Date or the Early Expiration Date, as applicable, as calculated by the Calculation Agent.

In the event that a notional investor (in the same position as the Issuer) would be unable to unwind its investments in the Reference-Portfolio Components by the Expiration Date or the Early Expiration Date, as applicable, the Issuer reserves the right to extend Expiration Date or the Early Expiration Date, as applicable, to such date where a notional investor in the Reference-Portfolio Components is able to fully unwind the Reference-Portfolio Components in cash.

For the avoidance of doubt, the Redemption Amount may include (but not be limited to) any costs arising from the Issuer unwinding any hedges in connection with the Product.

**Please note that the Redemption Amount may be less than the initially invested capital.**

**Early Redemption by Issuer** The Issuer is entitled to early redeem the Product in full quarterly, i.e. as of each 31 March, 30 June, 30 September and 31 December (the "**Early Early Expiration Date**") subject to at least 45 Business Days prior notice being given to the investors in the Product at the relevant Early Redemption Amount, and in any case not earlier than 30 September 2011 (if such date is not a Business Day, the next following Business Day shall apply) (such Early Redemption Date being subject to Market Disruption Event provisions).

**There is no Early Redemption right for the investor in this Product.**

**Reference-Portfolio Level** Sum of all Reference-Portfolio Components taking into consideration their respective weightings whereby a Reference-Portfolio Component is valued at the closing price published by the primary exchange of the Constituent and converted into the Settlement Currency at the prevailing exchange rate. The calculation also takes into account the effect of the Reference-Portfolio Fees and all other costs and expenses associated with the Reference Portfolio. The Reference-Portfolio Level is calculated for each Business Day by the Calculation Agent on the next Business Day.

If a Business Day is not an Exchange Business Day for any Reference-Portfolio Constituent, then the price for such Reference-Portfolio Constituent used to calculate the Reference-Portfolio Level will be the price of the previous Exchange Business Day for such Reference-Portfolio Constituent.

**Dividends** Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be re-invested into the Reference-Portfolio.

In respect of U.S. equity securities, for purposes of determining the amount of a dividend treated as notionally reinvested, such amount shall not be treated as reduced by the withholding tax imposed on dividends by Section 871(a) or 881(a) of the US Internal Revenue Code but shall instead be reduced by the 30% withholding tax imposed on dividend equivalents by Section 871(m) of the U.S. Internal Revenue Code of 1986, as amended.

## Product Structure

---

The Product allows for participation in the performance of the Reference-Portfolio. The Reference-Portfolio is a notional actively managed portfolio, created and maintained by the Reference-Portfolio Advisor. The Reference-Portfolio aims to replicate the performance of stocks and from time to time a cash position, less expenses. Any amounts reflecting net dividends of the Reference-Portfolio Constituents will be re-invested into the Reference-Portfolio.

## General Information

---

|   |  |
|---|--|
| Issuer                                      | UBS AG, Zurich   |
| Issuer Rating                               | Aa3 Moody's / A+ S&P's / A+ Fitch<br>For the avoidance of doubt, this is the long term credit rating of the Issuer and it does not represent ratings of the Product.   |
| Lead Manager                                | UBS AG, Zurich   |
| Calculation Agent                           | UBS AG, London Branch  |
| Paying Agent                                | UBS AG, Zurich   |
| Reference-Portfolio Advisor                 | Nevastar Finance Ltd.  |
| Swiss Paying Agent                          | UBS AG, Zurich   |
| Listing                                     | No listing   |
| Business Days                               | Any days on which the banks in London, Frankfurt a.M., Zurich and New York are open for business.  |
| Liquidity                                   | UBS intends to offer daily bid/offer prices depending on size and market conditions with a spread of 0.50%.<br><br>Indicative prices will be available on Reuters and Bloomberg  |
| Reference-Portfolio Fees (calculated daily) | Quarterly fee of 0.225% (0.90% per year) on the Reference-Portfolio Level accrued on a daily basis, plus (i) certain expenses commonly to be associated with establishing, maintaining and rebalancing a portfolio similar to the notional portfolio mirrored by the Reference-Portfolio and (ii) the Adjustment Fee, charged by the Calculation Agent and deducted from the Reference-Portfolio Level. The dates of the 0.225% fee deduction are 31 March, 30 June, 30 September and 31 December (in case any of the dates is not a Business Day, the next following Business Day will apply). <b>A part of the Reference-Portfolio Fee will be used to compensate the Reference-Portfolio Advisor.</b> |
| Rebalancing                                 | Rebalancing means any change in the Reference-Portfolio Components by the Reference-Portfolio Advisor after the Issue Date. The Calculation Agent has the right to reject Rebalancings under specific circumstances. The expected number of Rebalancings per year is 12.<br><br>In case of a Rebalancing, secondary market trading of the Product will be suspended until completion of the Rebalancing.   |
| Rebalancing / Adjustment Fee                | An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of a Constituent. The Adjustment Fee equals 0.20% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent.  |

|                              |   |
|------------------------------|---|
| Minimum Investment           | 1 Unit(s)   |
| Minimum Trading Lot          | 1 Unit(s)   |
| Clearing                     | SIX SIS, Euroclear, Clearstream (registered as intermediated securities with SIX SIS AG, in Switzerland)  |
| Form of deed                 | Uncertificated Securities   |
| Governing Law / Jurisdiction | Switzerland / Zurich  |
| Adjustments                  | The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation. |
| Public Offering              | Switzerland   |

### Tax Treatment Switzerland

|                          |   |
|--------------------------|---|
| Federal Stamp Duty       | The product is not subject to Swiss Federal Stamp Duty.   |
| Federal Income Tax       | The taxable income and capital gains/losses will be kept apart and will be reported to the Swiss Federal Tax Administration annually. Taxable income is subject to Swiss Federal, cantonal and communal income tax. |
| Withholding Tax          | The product is not subject to the Swiss withholding tax.  |
| EU Savings Tax Treatment | For Swiss paying agents, the product is not subject to the EU Savings tax.  |

The tax information only provides a general overview of the potential tax consequences linked to this product at the time of issue. Tax laws and tax doctrine may change, possibly with retroactive effect.

### Product Documentation

The Final Terms together with the 'General Terms and Conditions for Structured Products on Equity, Commodity and Index Underlyings', as amended from time to time ("General Terms and Conditions") shall form the entire documentation for this Product ("Product Documentation"), and accordingly the Final Terms should always be read together with the General Terms and Conditions. Definitions used in the Final Terms, but not defined therein shall have the meaning given to them in the General Terms and Conditions. Furthermore, the Final Terms shall serve as and fulfil the requirements of a 'Simplified Prospectus' in accordance with Art. 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). In the event that the Product is listed (see above item 'Listing' under 'General Information'), the Product Documentation will be amended in accordance with the listing requirements of the relevant Exchange.

During the whole term of this Product, the Product Documentation can be ordered free of charge from the Lead Manager at P.O. Box, CH-8098 Zurich (Switzerland), via telephone (+41-(0)44-239 47 03), fax (+41-(0)44-239 69 14) or via e-mail (swiss-prospectus@ubs.com). In addition, the Product Documentation is available on the internet at [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest).

Notices in connection with this Product shall be validly given by publication in electronic media such as Reuters and/or Investdata. In addition, any changes with regard to the terms of this Product shall be published on the internet at [www.ubs.com/keyinvest](http://www.ubs.com/keyinvest).

## Classification

---

This Product does not represent a participation in any of the collective investment schemes pursuant to Art. 7 ss of the Swiss Federal Act on Collective Investment Schemes (CISA) and thus does not require an authorisation of the Swiss Financial Market Supervisory Authority (FINMA). Therefore, investors in this Product are not eligible for the specific investor protection under the CISA.

Furthermore, this Product does not benefit from any depositor protection under Art. 37b under the Swiss Federal Law on Banks and Savings Banks (Banking Act) or other forms of deposit insurance under any other law as might be applicable to this Product.

## Prudential Supervision

---

UBS AG is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). In addition, its London Branch is authorised and regulated by the Financial Services Authority (FSA) and its Jersey Branch by the Jersey Financial Services Commission (JFSC).

## 2. Prospects of Profits and Losses

|                    |   |
|--------------------|---|
| Market Expectation | The Product is for Investors who expect the Underlying to increase over the life of the Product.  |
| Risk Tolerance     | <p>Investors in this product should be experienced investors and familiar with both derivative products and the stock markets.</p> <p>The Investors must be willing to make an investment that is exposed to the full down-side risk of the Underlying.</p> <p>Prior to the Expiration Date if the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product.</p> |
| Profit Potential   | <p>The Product allows for participation in the positive performance of the Underlying, as adjusted by various fees and expenses as described in more detail above.</p> <p>Prior to the Expiration Date if the Investor decides to buy/sell the Product under the Secondary Market terms (as detailed above), the Investor may also be exposed to any funding costs of the Issuer (including, but not limited to, any internal funding costs whether caused by changes in UBS's credit status or otherwise) in relation to the Product.</p>  |
| Loss Potential     | <p>The Investors may lose some or all of the investment as they are fully exposed to the performance of the Underlying.</p> <p>The Issuer is entitled to redeem the Product early.</p>  |

### 3. Significant Risks for Investors

**For product specific risks please see above (2. Prospects of Profits and Losses)**

#### **Risk Factors relating to the Issuer**

---

In addition to the market risk with regard to the development of the Underlying, each Investor bears the general risk that the financial situation of the Issuer could deteriorate. The Products constitute immediate, unsecured and unsubordinated obligations of the Issuer, which, particularly in case of insolvency of the Issuer, rank pari passu with each and all other current and future unsecured and unsubordinated obligations of the Issuer, with the exception of those that have priority due to mandatory statutory provisions. The general assessment of the Issuer's creditworthiness may affect the value of the Products. This assessment generally depends on the ratings assigned to the Issuer or its affiliated companies by rating agencies such as Moody's, Fitch and Standard & Poor's.

The Issuer Ratings indicated in this document reflect the situation at the time of issuance and may be subject to changes. The actual Issuer Ratings at any given time can be seen on the Issuer's website ([www.ubs.com](http://www.ubs.com)) under "Analysts & Investors".

#### **Secondary Market**

---

The Issuer or the Lead Manager, as applicable, intends, under normal market conditions, to provide bid and offer prices for this Product on a regular basis. However, the Issuer or the Lead Manager, as applicable, makes no firm commitment to provide liquidity by means of bid and offer prices for this Product, and assumes no legal obligation to quote any such prices or with respect to the level or determination of such prices. Potential Investors therefore should not rely on the ability to sell this Product at a specific time or at a specific price.

In special market situations, where the Issuer is completely unable to enter into hedging transactions, or where such transactions are very difficult to enter into, the spread between the bid and offer prices may be temporarily expanded, in order to limit the economic risks of the Issuer.

#### **Market Risk**

The investor is exposed to market disruption events (such as trading disruption, exchange disruption and early closure of the relevant exchange), adjustments and early termination which could have an impact on the redemption amount through delay in payment or change in value. For a detailed description of such events and their effects please read the General Terms and Conditions.

## Important Information

---

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which this document relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells this Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Products/Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS' prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the Products described herein, save where explicitly stated in the Product Documentation. The Products must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

There is a possibility that costs, including taxes, related to transactions in connection with this Product may arise for

## Selling Restrictions

---

**Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.**

**The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.**

**Europe** - For EEA jurisdictions (EU member states plus Norway, Iceland and Liechtenstein) that have implemented the EU Prospectus Directive ("EU-PD"), the Product Documentation for this Product DO NOT QUALIFY as a prospectus published in accordance with the requirements of the EU-PD. Unless and until a prospectus has been published in accordance with the requirements of the EU-PD, this Product may not be offered or sold in EEA jurisdictions that have implemented the EU-PD other than 1) in minimum denominations of, or total consideration per Investor of at least, EUR 50,000 (or equivalent in other currencies) or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 offerees that are not Qualified Investors per EEA jurisdiction. A "Qualified Investor" is a legal entity that (i) is authorised or regulated to operate in the financial markets or has the sole purpose to invest in securities; or (ii) meets two of the following three criteria (as shown in its last annual or consolidated accounts): (a) an average number of at least 250 employees during the last financial year; (b) a total balance sheet of more than EUR 43,000,000; and (c) an annual net turnover of more than EUR 50,000,000.

For EEA jurisdictions that have not implemented the EU-PD, sales must be in compliance with the law of that jurisdiction.

**Hong Kong** - The contents of this document have not been reviewed by any regulatory authority in Hong Kong. Investors are advised to exercise caution in relation to any offer. If an investor is in any doubt about any of the contents of this document, the investor should obtain independent professional advice.

**This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it.**

This Product has not been offered and sold, and each purchaser represents and agrees that it will not offer and sell the Product in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy and sell shares or debentures, whether as principal or agent, or in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) of Hong Kong or to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance, or in other



circumstances which do not result in the document being a "prospectus" within the meaning of the Companies Ordinance. In relation to the issue of this Product, each purchaser represents and agrees that it has not issued and will not issue any advertisement, invitation or document relating to the Product, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the Product which is or is intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance and any rules made thereunder.

**Singapore** - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275, of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

(a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

(b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,

securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except:

(1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA;

(2) where no consideration is or will be given for the transfer;

(3) where the transfer is by operation of law; or

(4) as specified in Section 276 (7) of the SFA.

**UK** - For the purposes of non-discretionary accounts, this Product should not be sold with a consideration of less than 50,000 EUR or equivalent.

**USA** - This Product may not be sold or offered within the United States or to U.S. persons, the foregoing shall not, however, prohibit sales to U.S. offices of UBS AG.

## Annex

### Reference-Portfolio Guidelines

#### Global Energy ex-MENA (USD) Reference-Portfolio

The Global Energy ex-MENA (USD) Reference-Portfolio (the "Reference-Portfolio") is a notional actively managed variable weight and composition total return portfolio, created and maintained by Nevastar Finance Ltd. (the "Reference-Portfolio Advisor"). The Reference-Portfolio aims to replicate (i) the performance of global stocks (the "Constituents") and (ii) from time to time, a cash position (the "Cash Position"), which together with the Constituents shall be referred to as the "Reference-Portfolio Components"), less expenses.

The Reference-Portfolio Components are selected by the Reference-Portfolio Advisor in accordance with the following guidelines (the "**Reference-Portfolio Guidelines**"):

1. Only shares of companies (the "**Investment Universe**") that are listed on stock exchanges with sufficient liquidity may be incorporated as Reference-Portfolio Constituents in the Reference-Portfolio ("**Eligible Shares**").
2. The number of Eligible Shares incorporated as Reference-Portfolio Constituents in the Reference-Portfolio may at no time be less than 10 or more than 30.
3. The weighting of an Eligible Share within the Reference-Portfolio may not exceed 20% of the Reference-Portfolio value.
4. The Reference-Portfolio may only reflect long positions in Eligible Shares.
5. The Cash Position may at no time exceed 10% of the value of the Reference-Portfolio.

In case of a rebalancing the theoretical volume of a buy or sell order for a Constituent is limited to 200% of the average traded daily volume of that Constituent. A rebalancing may happen at the discretion of the Reference-Portfolio Advisor. The theoretical volume is defined as the number of outstanding Certificates multiplied by the Reference-Portfolio Level (using a reasonable foreign exchange rate to convert into the currency of the Constituent) and multiplied by the change in the percentage weight of the Constituent. The average traded daily volume is defined as the 30 Day average trading turnover. The expected number of Rebalancings per year is 12.

At any time, the Reference-Portfolio may reflect a cash position which mirrors the holding of cash, money market instruments or cash obligations (the "Cash Position"). The Reference-Portfolio's exposure to cash may not exceed 10%. No interest will be paid on the Cash Position.

In calculating the level of the notional Reference-Portfolio, dividend payments for Eligible Shares contained in the Reference-Portfolio as Reference-Portfolio Constituents are taken into account on the corresponding Dividend Ex-Date within the Cash Position at the value of the distribution less any applicable taxes, as determined by the Reference-Portfolio Calculation Agent (the "**Net Dividend**").

The Reference-Portfolio fees comprise (i) a management fee at a rate of 0.225% per calendar quarter on the Reference-Portfolio Level (the "**Management Fee**") and (ii) an adjustment fee incurred with each adjustment of the notional Reference-Portfolio as of the Reference-Portfolio adjustment date (the "**Adjustment Fee**"). An Adjustment Fee is levied for each adjustment made in the Reference-Portfolio, and represents a percentage of the notional volume of each of the purchase and/or sale of an Eligible Share. The Adjustment Fee was set by the Reference-Portfolio Advisor in accordance with the Reference-Portfolio Calculation Agent at 0.20% as at the Launch Date. The Adjustment Fee can be adjusted by the Reference-Portfolio Calculation Agent. The Management Fee is accrued on a daily basis and paid on a quarterly basis, on 31 March, 30 June, 30 September and 31 December (should any of these dates fall on a day which is not a Business Day, the Fee is paid on the next Business Day).

The Reference-Portfolio is denominated in USD, while the Constituents, notionally comprised in the Reference-Portfolio, might be denominated in other currencies than USD. In order to appropriately reflect the performance of the Constituents in the determination of the value of the Reference-Portfolio, the value of the Constituents denominated in other currencies than USD is expressed in USD. The exchange rate equals the currently prevailing exchange rate. The exchange-rate risk is not mitigated.

The above Universe can be amended in agreement between the Calculation Agent and the Reference-Portfolio Advisor. Long positions may be based on stocks only. The Calculation Agent has the right to reject Constituents that form part of a Rebalancing.

The initial number of Constituents will be 24 and equally weighted:

| NAME   | TICKER         | Percentage |
|--|----------------|------------|
| Enterprise Products Partners L.P.            | EPD US Equity  | 4.167%     |
| El Paso Corp.                                | EP US Equity   | 4.167%     |
| BG Group PLC                                 | BG/ LN Equity  | 4.167%     |
| Santos Limited                               | STO AU Equity  | 4.167%     |
| Reliance Industries Ltd. ADR                 | RIGD LI Equity | 4.167%     |
| Chevron Corp.                                | CVX US Equity  | 4.167%     |
| Canadian Natural Resources Ltd.              | CNQ CN Equity  | 4.167%     |
| CNOOC Limited                                | 883 HK Equity  | 4.167%     |
| TransCanada Corp.                            | TRP CN Equity  | 4.167%     |
| Marathon Oil Corp.                           | MRO US Equity  | 4.167%     |
| Gazprom ADR                                  | OGZD LI Equity | 4.167%     |
| Petrobras ADR                                | PBR US Equity  | 4.167%     |
| Devon Energy Corp.                           | DVN US Equity  | 4.167%     |
| China Petroleum and Chemical Corp. (Sinopec) | 386 HK Equity  | 4.167%     |
| Suncor Energy Inc.                           | SU CN Equity   | 4.167%     |
| NovaTek OAO ADR                              | NVTK LI Equity | 4.167%     |
| LUKOIL ADR                                   | LKOD LI Equity | 4.167%     |
| ConocoPhillips                               | COP US Equity  | 4.167%     |
| PetroChina Company Limited                   | 857 HK Equity  | 4.167%     |
| Statoil ASA                                  | STL NO Equity  | 4.167%     |
| Woodside Petroleum Limited                   | WPL AU Equity  | 4.167%     |
| Halliburton Company                          | HAL US Equity  | 4.167%     |
| National Oilwell Varco Inc.                  | NOV US Equity  | 4.167%     |
| Baker Hugs Incorporated                      | BHI US Equity  | 4.167%     |